KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Development and Effects of a Smartphone Application to Improve Self-Management in Workers Who Underwent Thyroid Cancer Surgery. PMID 39792358 · Cancer Nurs · 2026 Jul The study is an RCT in oncology, but it is ineligible because it does not have a drug-containing intervention and does not have a primary time-to-event efficacy endpoint. The endpoints are patient-reported outcomes and lifestyle measures.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of Auricular Acupressure Combined With Positive Psychological Techniques on Sleep Quality in Cancer Patients Undergoing Radiotherapy: A Randomized Controlled Trial. PMID 39655909 · Cancer Nurs · 2026 Jul The study is an oncology RCT in humans but is excluded because it tests non-drug interventions and does not measure a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Benefits of an anti-inflammatory diet compared to a low-residue diet during concurrent chemoradiation therapy for patients with locally advanced cervical cancer: a randomized clinical trial. PMID 42516234 · Front Nutr · 2026 The trial compares two dietary interventions (anti-inflammatory diet vs. low-residue diet) in patients receiving standard chemoradiation. While it is a randomized oncology trial with an OS endpoint, the intervention under investigation is non-drug. Therefore, it does not meet the criterion of a 'drug-containing intervention'.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tegileridine versus Sufentanil Patient-Controlled Intravenous Analgesia for Gastrointestinal Recovery in Elderly Patients Undergoing Laparoscopic Colorectal Cancer Surgery: A Randomized Controlled Trial. PMID 42504203 · Drug Des Devel Ther · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A phase II clinical trial of neoadjuvant chemotherapy combined with immunotherapy and different radiotherapy fractionation regimens in HR+/HER2- breast cancer. PMID 42495649 · Front Immunol · 2026 仅有 Phase I/II 证据,未达到确证性随机试验标准。
H B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Fuzheng Huayu tablets reduces the risk of further decompensation after the first decompensation in patients with HBV-related cirrhosis: protocol for a randomized, double-blind, placebo-controlled, multicenter trial. PMID 42465987 · Front Pharmacol · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Liposomal Bupivacaine for Serratus Anterior Plane Block in Modified Radical Mastectomy: Protocol for a Randomized, Double-Blind Trial Evaluating Pain-Related and Early Recovery Outcomes. PMID 42438817 · J Pain Res · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Mechanism-matched Helicobacter pylori treatment in the potassium-competitive acid blocker era. PMID 42434006 · Front Med (Lausanne) · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Early divergence of treatment response trajectories to adalimumab or its biosimilar in active ankylosing spondylitis: consensus clustering analysis of a randomized controlled trial. PMID 42416060 · Front Immunol · 2026 Study is a Phase III randomized trial with drug intervention and original results, but it is not an oncology study (ankylosing spondylitis) and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier curves/hazard ratios for survival or disease progression.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of Jishi Shuanghua Granules in preventing radiation-induced esophagitis in non-small cell lung cancer patients undergoing concurrent chemoradiotherapy: protocol for a multicenter, randomized, double-blind, placebo-controlled trial. PMID 42415804 · Front Med (Lausanne) · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Modified sini powder for the management of postoperative depression in non-small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial protocol. PMID 42403716 · Front Pharmacol · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Pharmacoeconomic evaluation of first-line tislelizumab for extensive-stage small cell lung cancer using a comparative validation of traditional survival and machine learning models. PMID 42388757 · Front Public Health · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The effect of preoperative stellate ganglion block on postoperative delirium in elderly patients undergoing gastrointestinal oncologic surgery: protocol for a randomized, double-blind, sham-controlled trial. PMID 42383021 · Front Neurol · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The efficacy of angiogenesis inhibitors combined with chemotherapy in advanced breast cancer: a systematic review and meta-analysis. PMID 42376666 · Front Oncol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study. PMID 42368972 · Cancer Commun (Lond) · 2026 The study is a Phase III randomized oncology trial with a drug intervention reporting original primary results. However, the primary endpoint is objective response rate (ORR), which is a categorical endpoint, not a time-to-event endpoint like overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), event-free survival (EFS), recurrence-free survival (RFS), time to progression (TTP), or an analysis based on Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the cohort's requirement for a time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Exercise During Chemotherapy Treatment as an Adjuvant Programme in Patients With Lymphoma (EDONOLA): Study Protocol for a Randomised Controlled Trial. PMID 42343877 · Cancer Control · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Comment on "Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003". PMID 42336600 · Pract Radiat Oncol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
CT Perfusion Blood Flow Provides an Early Response Marker for Progression-free Survival in a Prospective Randomized Clinical Trial of Metastatic Renal Cell Carcinoma. PMID 42308169 · Technol Cancer Res Treat · 2026 The record is from a randomized trial in oncology with a time-to-event endpoint and drug intervention, but the specific analysis described is secondary, focusing on a biomarker (CT perfusion blood flow) as a predictor of PFS, not the primary report of the drug efficacy trial. The phase (III/IIIb or II/III) is not explicitly stated in the provided metadata, preventing definitive eligibility.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy and safety of TiaoPi AnChang decoction to reduce CAPOX-Induced adverse reactions in Chinese patients with colorectal cancer: a randomized, double-blind, placebo-controlled trial. PMID 42292820 · Front Pharmacol · 2026 The study is a randomized, placebo-controlled trial in oncology with a drug intervention, but it is an interim analysis focusing on adverse reactions, not a time-to-event efficacy endpoint. The phase is not specified (only a registration number is given, not a trial phase), and the predefined survival endpoints had not been reached. Therefore, it does not meet the criteria for a Phase III/IIIb or Phase II/III randomized trial with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of time-of-day on immune checkpoint inhibitor therapy in cancer patients: an up-to-date clinical review. PMID 42292486 · Front Immunol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Auricular acupuncture for insomnia in female patients with non-metastatic breast cancer: study protocol for a multicenter, randomized, controlled clinical trial. PMID 42267158 · Front Psychiatry · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The Effect of a Program Based on the Common-Sense Model on Illness Perception and Health-Promoting Behaviors in Women with Breast Cancer: A Randomized Clinical Trial Study. PMID 42256750 · Iran J Nurs Midwifery Res · 2026 The study is an original, randomized, human oncology trial reporting results, but it is ineligible because it lacks a drug-containing intervention (it tests an educational program) and does not measure a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The phase is not specified, but it is not a definitive Phase II/III or III/IIIb trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prospective randomized trial of tumor-treating fields with chemoradiation in newly diagnosed glioblastoma. PMID 42239656 · Neurooncol Adv · 2026 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy evaluation of Wenxin Keli in treating anthracycline-induced atrial arrhythmias (WARMA study): protocol for a multicenter, randomized, double-blind, placebo-controlled clinical trial. PMID 42232310 · Front Cardiovasc Med · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
SAFETY AND EFFECTIVENESS OF BLUE EYE HYPERTONIC SOLUTION VERSUS SALINE SOLUTION IN THE TREATMENT OF FLAT COLONIC LESIONS: A RANDOMIZED CLINICAL TRIAL. PMID 42207084 · Arq Gastroenterol · 2026 Study is a small, randomized trial of an endoscopic solution (Blue Eye vs. saline) for EMR of flat colonic lesions. While oncology-related and randomized, it fails key criteria: (1) phase is not specified as Phase III/IIIb or Phase II/III; (2) intervention is a procedural adjunct (hypertonic solution), not a systemic drug therapy; (3) endpoints are technical performance outcomes (margins, volume), not time-to-event efficacy endpoints (OS, PFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of Songjiao Dihuang Tang decoction for the dynamic/adaptive treatment of immune checkpoint inhibitor-associated myocarditis: study protocol and statistical analysis plan for a stop&go, multicentre, randomized, parallel-controlled, double-blind, superiority clinical trial. PMID 42206175 · Front Pharmacol · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Sintilimab plus fruquintinib with or without radiotherapy for third-line treatment of colorectal cancer with liver metastases: study protocol for a randomized controlled, multicenter phase II trial. PMID 42206059 · Front Immunol · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Mixed-Method Formative Evaluation and Cultural Adaptation of Digital Health Communication Content and Delivery Promoting Lung Cancer Screening Shared Decision-Making. PMID 42201308 · Cancer Control · 2026 Eligibility excluded because the study lacks a drug-containing intervention and does not report a time-to-event efficacy endpoint. It is a formative evaluation of a digital health communication tool for lung cancer screening shared decision-making, not a randomized trial of a therapeutic drug with survival or progression outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Moxibustion for gastrointestinal cancer-related fatigue: study protocol for a randomized clinical trial. PMID 42199916 · Front Psychiatry · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906). PMID 42183251 · Front Immunol · 2026 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Timely Integration of specialist palliative care into oncology care for patients receiving radiotherapy for bone metastases: A study procotol for the TIPZO-RT Randomized Controlled Trial. PMID 42172282 · PLoS One · 2026 This is a protocol for a randomized trial evaluating a non-drug palliative care intervention with a primary endpoint of patient satisfaction. It lacks original results, does not involve a drug intervention, and does not have a primary time-to-event efficacy endpoint (OS, PFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Carcinoembryonic Antigen Flare Under Oxaliplatin-Based Chemotherapy Predicts Benefit from Nivolumab in Metastatic Microsatellite-Stable Colorectal Cancer - A Post Hoc Analysis of METIMMOX Trial Data. PMID 42158080 · Immunotargets Ther · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Twenty-year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer. PMID 42141924 · CA Cancer J Clin · 2026 The study is a randomized, oncology trial with time-to-event endpoints, but it evaluates a radiotherapy intervention (internal mammary and medial supraclavicular lymph node irradiation) and does not involve a drug-containing intervention arm, which is required for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Preventive effect of transcutaneous electrical acupoint stimulation pretreatment on lymphedema in patients undergoing axillary lymph node dissection for breast cancer: a randomized controlled trial protocol. PMID 42137144 · Front Oncol · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The therapeutic potential of epimedium and its bioactive flavonoids in hepatitis and cirrhosis: an integrative review. PMID 42100655 · Front Cell Infect Microbiol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Personalized swallowing rehabilitation program for post-surgical dysphagia in oral cancer patients: a randomized controlled trial. PMID 42100422 · Front Oncol · 2026 The study is a randomized controlled trial in oral cancer patients evaluating a non-drug rehabilitation intervention with functional (FOIS) and patient-reported (MDADI) outcomes. It lacks a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Favorable safety outcomes of a perioperative propranolol and etodolac regimen in cancer patients in four randomized controlled trials. PMID 42088573 · Front Pharmacol · 2026 The report is a safety-focused analysis of four RCTs, with efficacy outcomes (DFS, OS) presented as secondary/exploratory endpoints. The trial phase is not explicitly stated, and the primary purpose is to evaluate safety, not to present formal efficacy results from a definitive Phase III or equivalent trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Brief report: Artificial intelligence meets small cell lung cancer-integrating clinicopathological and wholeslide image data for prognostic prediction in SCLC. PMID 42088381 · Front Artif Intell · 2026 This is a secondary analysis of data from the phase IIIB CANTABRICO trial to validate an AI-based prognostic model. While it involves a phase III trial and time-to-event endpoints, the report itself does not present the primary efficacy results of a drug-containing intervention from a randomized trial. It is a predictive biomarker/model validation study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
RNI Precision Trial Protocol: Optimization of Regional Node Irradiation for Sentinel Lymph Node-positive Breast Cancer Omitting Axillary Dissection Based on Clinical and Genomic Risk Assessment: A Prospective Clinical Trial. PMID 42081886 · Technol Cancer Res Treat · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and safety of transcutaneous electrical acupoint stimulation and acupressure in alleviating chemotherapy-related adverse reactions in female patients with breast cancer: a randomized clinical trial. PMID 42063721 · Front Oncol · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effects of mindfulness yoga intervention on physical function, anxiety, inflammatory response, and relapse intention in methamphetamine addicts: a 24-week randomized controlled trial. PMID 42058068 · Front Public Health · 2026 The study is a randomized controlled trial but is not an oncology trial. It investigates a non-drug (yoga/mindfulness) intervention for methamphetamine addiction and does not involve a human malignant neoplasm. There is no drug intervention and no primary/key secondary time-to-event efficacy endpoint (like OS, PFS, DFS, etc.) relevant to oncology Kaplan-Meier digitization.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of total intravenous anesthesia on postoperative quality of recovery and the levels of inflammatory factors in patients undergoing retroperitoneal endoscopic surgery in urology: Study protocol for a randomized, controlled trial. PMID 42054415 · PLoS One · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Clinical efficacy of comprehensive traditional Chinese medicine in adjuvant therapy for stage Ib-IIIa resected non-small cell lung cancer: a multi-center, randomized, double-blind, placebo-controlled trial. PMID 42038290 · Front Pharmacol · 2026 The record fails the 'phase3_or_definitive' criterion because the trial phase is not explicitly established in the provided metadata. While it is a definitive-sized randomized trial (n=286) with a time-to-event endpoint, the criteria require explicit evidence of a Phase III/IIIb or Phase II/III designation, which is absent.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of Oxycodone versus Sufentanil-Based Intravenous Patient-Controlled Multimodal Analgesia on Early Gastrointestinal Recovery and Pain After Laparoscopic Colorectal Cancer Surgery: A Randomized Double-Blind Trial. PMID 42005586 · J Pain Res · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Unguided web-based brief intervention with genetic risk education to reduce unhealthy alcohol consumption in Japan: Protocol for a randomized controlled trial. PMID 41996377 · PLoS One · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Remimazolam versus propofol for postoperative ICU sedation in mechanically ventilated cancer patients: a noninferiority randomized clinical trial. PMID 41988528 · Front Pharmacol · 2026 The study is an oncology-related randomized trial with a drug intervention and original results. However, it is excluded because it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, TTP, Kaplan-Meier, HR). The primary outcomes are pharmacodynamic (time to achieve sedation, percentage of time in sedation range), and secondary outcomes include mortality but without time-to-event analysis reported. The phase is not explicitly stated, and the trial is not identified as a definitive Phase III/IIIb or II/III trial. Therefore, it does not meet the criteria for inclusion in this cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nutritional prehabilitation in head and neck cancer patients (PreHead) - A randomized controlled trial study protocol. PMID 41984990 · PLoS One · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effect of Prehabilitation-Based Individualized Dietary Guidance on Nutrition and Short-Term Quality of Life in Locally Advanced Gastric Cancer Patients Undergoing Surgery: A Single-Center Randomized Controlled Trial. PMID 41969312 · J Multidiscip Healthc · 2026 The record describes a randomized trial in oncology patients (locally advanced gastric cancer) but does not meet key eligibility criteria. It is not a drug-intervention study; the intervention is 'individualized dietary guidance based on the prehabilitation concept'. It does not report a primary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Endpoints are nutritional outcomes, quality of life, and postoperative safety. The trial phase is not specified as definitive (Phase III/IIIb or Phase II/III). Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prevention of oral mucositis in patients undergoing cancer chemotherapy using betamethasone mouthwash: A multicenter randomized controlled trial protocol. PMID 41950207 · PLoS One · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Hypomagnesemia Associated with Omeprazole Use in Patients Treated with Platinum Derivatives: An Exploratory Randomized Placebo-Controlled Clinical Trial. PMID 41938717 · Can J Hosp Pharm · 2026 The record describes a randomized trial with a drug intervention and mentions Kaplan-Meier analysis. However, the primary endpoint is the rate of magnesium depletion (a safety/biomarker outcome), not a key oncologic time-to-event efficacy endpoint. Furthermore, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III, and the study is exploratory in nature, focusing on safety rather than treatment efficacy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -